We are live on ! Find out more
EC

Elmind Capital Portfolio holdings

AUM $398M Turnover 23.08%
This Fund
S&P 500
This Quarter Est. Return
+51.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$339M
AUM Growth
–
Cap. Flow
+$288M
Cap. Flow %
85.07%
Top 10 Hldgs %
68.55%
Holding
34
New
34
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$32.9M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$32.4M
3
VRDN icon
Viridian Therapeutics
VRDN
+$23.5M
4
CLDX icon
Celldex Therapeutics
CLDX
+$22.8M
5
CGON icon
CG Oncology
CGON
+$20.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
URGN icon
26
UroGen Pharma
URGN
$1.79B
$2.34M 0.69%
+100,000
New +$2.17M
2025 Q4
0 quarters
IMCR icon
27
Immunocore
IMCR
$1.52B
$2.02M 0.6%
+58,248
New +$2.06M
2025 Q4
0 quarters
DSGN icon
28
Design Therapeutics
DSGN
$656M
$1.95M 0.58%
+207,900
New +$1.63M
2025 Q4
0 quarters
ENGN icon
29
enGene Therapeutics
ENGN
$115M
$1.9M 0.56%
+210,000
New +$1.68M
2025 Q4
0 quarters
ALEC icon
30
Alector
ALEC
$213M
$1.4M 0.41%
+900,000
New +$1.6M
2025 Q4
0 quarters
AMLX icon
31
Amylyx Pharmaceuticals
AMLX
$3.47B
$1.35M 0.4%
+112,000
New +$1.52M
2025 Q4
0 quarters
APLS icon
32
DELISTED
Apellis Pharmaceuticals
APLS
$1.26M 0.37%
+50,000
New +$1.17M
2025 Q4
0 quarters
SUPN icon
33
Supernus Pharmaceuticals
SUPN
$2.3B
$994K 0.29%
+20,000
New +$972K
2025 Q4
0 quarters
EWTX icon
34
Edgewise Therapeutics
EWTX
$4.15B
$744K 0.22%
+30,000
New +$602K
2025 Q4
0 quarters
1
2

Similar funds

FFS
Fischer Financial Services Harrisburg, Pennsylvania $398M AUM 22.91% 1-Year Est. Return
SFS
Stiles Financial Services Edina, Minnesota $398M AUM 55.89% 1-Year Est. Return
SIC
Shoker Investment Counsel Oxford, Ohio $398M AUM 39.01% 1-Year Est. Return
SIAS
Summit Investment Advisory Services Roseville, Minnesota $398M AUM 21.26% 1-Year Est. Return
HVP
Hudson Value Partners Palm Beach, Florida $399M AUM 48.26% 1-Year Est. Return
AC
Alfreton Capital Radlett, Hertfordshire, United Kingdom $399M AUM 20.53% 1-Year Est. Return
W
WorthPointe La Jolla, California $399M AUM 22.49% 1-Year Est. Return
CL
COWA LLC Tulsa, Oklahoma $399M AUM 25.74% 1-Year Est. Return

Elmind Capital's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Elmind Capital, which disclosed 34 positions worth $339M. Its ten largest holdings account for 69% of the portfolio.

Its largest position is Cogent Biosciences: 1,170,740 shares worth $41.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Elmind Capital's largest Q4 2025 buy was Cogent Biosciences: 1,170,740 shares worth $41.6M.
  • Elmind Capital's ten largest holdings make up 69% of its $339M portfolio in Q4 2025.
  • Elmind Capital disclosed 34 positions in Q4 2025, its first 13F filing on record.

Based on Elmind Capital's 13F filing for Q4 2025, filed 17 Feb 2026.